Crossmark

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial

Crossref DOI link: https://doi.org/10.1038/s41467-025-59865-1

Published Online: 2025-05-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Zhigang https://orcid.org/0000-0003-4043-3196
Wang, Dong

Li, Guanjun

Yi, Muhua

Zhang, Zhaoyuan

Zhong, Guihua

Xu, Liangfu

Jiang, Rong

Zheng, Yannan

Huang, Linxuan

Peng, Yingpeng

Liang, Lizhong

Li, Jianpeng

Liu, Ye

Lai, Jun

Lv, Xianjuan

Xu, Yongqiang

Liu, Qiaodan

Wang, Zhiqiang

Liu, Zhutian

Yang, Qinan

Nie, Li

Lei, Jiao

Huang, Xiaotao

Liu, Zhijie

Jiang, Wen https://orcid.org/0000-0001-9154-633X
Funding

Funding for this research was provided by:

Chinese Society of Clinical Oncology (Grant Y-Young2022—0225)
License Information

Text and Data Mining valid from 2025-05-17

Version of Record valid from 2025-05-17
More Information

Article History

Received: 15 October 2024

Accepted: 7 May 2025

First Online: 17 May 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below